Education
About Us
Working with TipRanks
Follow Us
Carlsmed, Inc. (CARL)
NASDAQ:CARL
CARL Analyst Ratings
Strong Buy
5 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
CARL Stock 12 Month Forecast
Average Price Target
$18.40
▲(41.10% Upside)
| Highest Price Target$21.00 | Average Price Target$18.40 | Lowest Price Target$16.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Truist Financial
$18
Buy
38.04%
Upside
Initiated
08/18/25
Bank of America Securities
$16
Buy
22.70%
Upside
Initiated
08/18/25
Buy Rating for Carlsmed: Innovative Aprevo Technology and Strong Growth Projections Justify Premium ValuationWe are initiating coverage on Carlsmed (CARL) with a Buy rating and $16 PO. Platform is pioneering a new standard of care in spine fusion surgery with custom 3D printed interbody implants and an AI enabled surgical planning software. The made to order implants custom fit unique vertebral space of each patient, helping surgeons achieve better alignment outcomes, resulting lower revision surgery rates. CARL’s revision rates are 1.5%/3.5% at 1 year /2 years (vs traditional spine at 8.7%/14.4%). Surgeon adoption likely source of upside to our model We forecast CARL will add ~20-25 new surgeons each quarter through 2027. This is likely conservative. We think surgeons will adopt as spine surgeons favor new tech and KOL feedback has been positive (see inside for quotes from our diligence).
BTIG
$21
Buy
61.04%
Upside
Initiated
08/18/25
Piper Sandler
$18
Buy
38.04%
Upside
Initiated
08/18/25
Goldman Sachs
$19
Buy
45.71%
Upside
Initiated
08/17/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Truist Financial
$18
Buy
38.04%
Upside
Initiated
08/18/25
Bank of America Securities
$16
Buy
22.70%
Upside
Initiated
08/18/25
Buy Rating for Carlsmed: Innovative Aprevo Technology and Strong Growth Projections Justify Premium ValuationWe are initiating coverage on Carlsmed (CARL) with a Buy rating and $16 PO. Platform is pioneering a new standard of care in spine fusion surgery with custom 3D printed interbody implants and an AI enabled surgical planning software. The made to order implants custom fit unique vertebral space of each patient, helping surgeons achieve better alignment outcomes, resulting lower revision surgery rates. CARL’s revision rates are 1.5%/3.5% at 1 year /2 years (vs traditional spine at 8.7%/14.4%). Surgeon adoption likely source of upside to our model We forecast CARL will add ~20-25 new surgeons each quarter through 2027. This is likely conservative. We think surgeons will adopt as spine surgeons favor new tech and KOL feedback has been positive (see inside for quotes from our diligence).
BTIG
$21
Buy
61.04%
Upside
Initiated
08/18/25
Piper Sandler
$18
Buy
38.04%
Upside
Initiated
08/18/25
Goldman Sachs
$19
Buy
45.71%
Upside
Initiated
08/17/25
Best Analysts Covering Carlsmed, Inc.
1 Month
xxx
Success Rate
0/1 ratings generated profit
Average Return
-8.40%
initiated a xxx
rating 7 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 0.00% of your transactions generating a profit, with an average return of -8.40% per trade.
3 Months
xxx
Success Rate
0/1 ratings generated profit
Average Return
-8.40%
initiated a xxx
rating 7 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 0.00% of your transactions generating a profit, with an average return of -8.40% per trade.
1 Year
Success Rate
0/1 ratings generated profit
Average Return
-8.40%
initiated a buy rating 7 days ago
Copying Richard Newitter's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -8.40% per trade.
2 Years
xxx
Success Rate
0/1 ratings generated profit
Average Return
-8.40%
initiated a xxx
rating 7 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -8.40% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
CARL Analyst Recommendation Trends
Rating
Aug 25
Strong Buy
1
Buy
3
Hold
0
Sell
0
Strong Sell
0
total
4
Each month's total comprises the sum of three months' worth of ratings.
CARL Financial Forecast
CARL Stock Forecast FAQ
What is CARL’s average 12-month price target, according to analysts?
Based on analyst ratings, Carlsmed, Inc.’s 12-month average price target is 18.40.
What is CARL’s upside potential, based on the analysts’ average price target?
Carlsmed, Inc. has 41.10% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is CARL a Buy, Sell or Hold?
Carlsmed, Inc. has a consensus rating of Strong Buy which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.
What is Carlsmed, Inc.’s price target?
The average price target for Carlsmed, Inc. is 18.40. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $21.00 ,the lowest forecast is $16.00. The average price target represents 41.10% Increase from the current price of $13.04.
The highest analyst price target is $21.00 ,the lowest forecast is $16.00. The average price target represents 41.10% Increase from the current price of $13.04.
What do analysts say about Carlsmed, Inc.?
Carlsmed, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
How can I buy shares of CARL?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.